Nagaoka Red Cross Hospital
9
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients
Role: lead
A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years
Role: lead
Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus
Role: collaborator
Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus
Role: lead
Long-term of 10 Years Results of a Prospective Longitudinal Study
Role: lead
Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus
Role: lead
Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium
Role: lead
Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Type 2 Diabetic Patients
Role: lead
A Cohort Study of Morning Home Blood Pressure Measurement in Type 2 Diabetic Patients
Role: lead
All 9 trials loaded